FDA calendar · September 2024 · built from SEC filings

PDUFA dates September 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in September 2024: NEREUSTM (September 18), RPRX (September 26). The FDA calendar also recorded 63 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in September 2024

2 PDUFA target action dates in September 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
September 18, 2024Vanda Pharmaceuticals Inc.VNDANEREUSTM (tradipitant)symptoms of gastroparesis to a final decision priorSEC Form 10-Q, filed 2025-10-30
September 26, 2024Royalty Pharma plcRPRXNot namedschizophrenia in adultsSEC Form 10-K, filed 2025-02-12

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

September 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Sep 2024Month disclosedOcrevus® (ocrelizumab)HALOFDA approval—ApprovedSEC Form 10-K
Sep 2024Month disclosedZYNRELEF® (bupivacaine-meloxicam)HRTXFDA approval—ApprovedSEC Form 10-K
Sep 2024Month disclosedYUTREPIA (treprostinil)LQDANDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
Sep 2024Month disclosed—SNYFDA approval—ApprovedSEC 8-K Exhibit 99.1
Sep 2024Month disclosed—SPRYNDA/BLA submissionType I allergic reactionsCompletedSEC 8-K Exhibit 99.1
Sep 2024Month disclosedFILSPARI (sparsentan)TVTXFDA approvalprimary IgANApprovedSEC Form 10-Q
Sep 2024Month disclosedCOBENFYZLABFDA approval—ApprovedSEC Form 10-Q
September 3, 2024oxylanthanumUNCYNDA/BLA submissionhyperphosphatemia in patients with chronic kidney diseaseCompletedSEC Form 10-Q
September 5, 2024FILSPARI (sparsentan)TVTXLabel expansion—ApprovedopenFDA Drugs@FDA
September 11, 2024Tremfya (guselkumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
September 12, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 13, 2024Ebglyss (lebrikizumab-lbkz)LLYFDA approvalTo treat moderate-to-severe atopic dermatitisApprovedFDA Novel Drug Approvals
September 16, 2024—LQDANDA/BLA accepted—CompletedSEC Form 10-Q
September 17, 2024Fasenra (benralizumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2024Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2024KISQALI® (ribociclib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
September 18, 2024NEREUSTM (tradipitant)VNDAComplete Response Letter—CRL issuedSEC Form 10-K
September 19, 2024Rybrevant (amivantamab-vmjw)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
September 20, 2024Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 20, 2024Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 20, 2024Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
September 25, 2024Tagrisso® (osimertinib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
September 26, 2024Yervoy® (ipilimumab)BMYAdvisory committee—CompletedFDA advisory committee calendar
September 26, 2024Opdivo® (nivolumab)BMYAdvisory committee—CompletedFDA advisory committee calendar
September 26, 2024Cobenfy (trospium chloride; xanomeline tartrate)BMYFDA approvalTo treat schizophreniaPress ReleaseApprovedFDA Novel Drug Approvals
September 26, 2024KEYTRUDA® (pembrolizumab)MRKAdvisory committee—CompletedFDA advisory committee calendar
September 26, 2024Tevimbra (tislelizumab-jsgr)ONCAdvisory committeesame proposed indicationCompletedFDA advisory committee calendar
September 27, 2024Retevmo (selpercatinib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
September 27, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 30, 2024protocol (AMP-511)AIMFDA approval—ApprovedSEC Form 10-Q
September 30, 2024RyoncilMESOFDA approval—ApprovedSEC 8-K Exhibit 99.1
September 30, 2024Adcirca® (tadalafil)ONCOFDA approval—ApprovedSEC Form 10-Q
September 30, 2024—PCRXFDA approval—ApprovedSEC 8-K Exhibit 99.1
September 30, 2024—SPRYFDA approval—ApprovedSEC Form 10-Q
September 30, 2024SirolimusEFR (sirolimus)WHWKFDA approval—ApprovedSEC 8-K Exhibit 99.1
September 30, 2024—XFORFDA approval—ApprovedSEC Form 10-Q

September 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Sep 2024Month disclosedJuvmo (tavapadon)ABBVTopline readout—PositiveSEC Form 10-K
Sep 2024Month disclosedVYGLXIA (troriluzole)BHVNTopline readout—PositiveSEC 8-K Exhibit 99.1
Sep 2024Month disclosedSPINRAZA (nusinersen)BIIBTopline readout—PositiveSEC Form 10-K
Sep 2024Month discloseddapirolizumab pegolBIIBTopline readoutmoderate-to-severe SLEPositiveSEC Form 10-K
Sep 2024Month disclosedextension (SPY004)DYNTopline readout—PositiveSEC Form 10-K
Sep 2024Month disclosedEDP-323ENTATopline readout—PositiveSEC 8-K Exhibit 99.1
Sep 2024Month disclosedlosmapimodFULCTopline readout—MixedSEC Form 10-Q
Sep 2024Month disclosedfosgonimetonLONATopline readout—Missed primary endpointSEC Form 10-Q
Sep 2024Month disclosedDA-1726MTVATopline readoutobesityPositivesec_424b
Sep 2024Month disclosedVAX-31PCVXTopline readout—PositiveSEC Form 10-Q
Sep 2024Month disclosedsuperoxide (REC-994)RXRXTopline readout—Met primary endpointSEC Form 10-K
Sep 2024Month disclosed—VRDNTopline readout—PositiveSEC Form 10-K
September 6, 2024JX02002MISTTopline readoutPSVT in ChinaPositiveSEC Form 10-Q
September 19, 2024EDG-7500EWTXTopline readoutoHCMPositivesec_424b

September 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Sep 2024Month disclosedIGALMI® (dexmedetomidine)BTAIQTrial start—CompletedSEC Form 8-K
September 25, 2024CRS3123ACXPTrial start—CompletedSEC Form 10-K
Sep 2024Month disclosedBH-2100BHVNTrial start—CompletedSEC Form 10-Q
Sep 2024Month disclosedBHV-2100BHVNTrial start—CompletedSEC 8-K Exhibit 99.1
Sep 2024Month disclosedINDV-6001SUPNTrial start—CompletedSEC Form 10-K
Sep 2024Month disclosedarrows (MC138)RNAZTrial start—CompletedSEC Form 10-Q
Sep 2024Month disclosedREC-1245RXRXTrial start—CompletedSEC Form 10-K
Sep 2024Month disclosedaritinercept (AUR200)AUPHTrial start—CompletedSEC 8-K Exhibit 99.1
Sep 2024Month disclosedCLN-619CGEMTrial startrelapsed/refractory multiple myelomaCompletedSEC Form 10-K
Sep 2024Month disclosedCDI-988COCPTrial start—Completedsec_s1
Sep 2024Month disclosedMZE782MAZETrial start—Completedsec_424b
September 30, 2024CUE-101CUETrial start—CompletedSEC Form 10-Q

25 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps September 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in September 2024?

2 PDUFA dates fell in September 2024: NEREUSTM (September 18), RPRX (September 26). The FDA calendar also recorded 63 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.